Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 65

Cited In for PubMed (Select 20080969)

1.

Altered Cholesterol Intracellular Trafficking and the Development of Pathological Hallmarks of Sporadic AD.

Chen X, Hui L, Soliman ML, Geiger JD.

J Parkinsons Dis Alzheimers Dis. 2014;1(1). pii: 8.

2.

Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.

Caldwell CC, Yao J, Brinton RD.

Neurotherapeutics. 2015 Jan;12(1):66-80. doi: 10.1007/s13311-014-0324-8.

PMID:
25534394
3.

Resveratrol as a therapeutic agent for Alzheimer's disease.

Ma T, Tan MS, Yu JT, Tan L.

Biomed Res Int. 2014;2014:350516. doi: 10.1155/2014/350516. Epub 2014 Nov 26.

4.

Our "energy-Ca(2+) signaling deficits" hypothesis and its explanatory potential for key features of Alzheimer's disease.

Chen M, Nguyen HT.

Front Aging Neurosci. 2014 Dec 3;6:329. doi: 10.3389/fnagi.2014.00329. eCollection 2014.

5.

Effect of the CALHM1 G330D and R154H human variants on the control of cytosolic Ca2+ and Aβ levels.

Vingtdeux V, Tanis JE, Chandakkar P, Zhao H, Dreses-Werringloer U, Campagne F, Foskett JK, Marambaud P.

PLoS One. 2014 Nov 11;9(11):e112484. doi: 10.1371/journal.pone.0112484. eCollection 2014.

6.

Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment.

Pasinetti GM, Wang J, Ho L, Zhao W, Dubner L.

Biochim Biophys Acta. 2015 Jun;1852(6):1202-1208. doi: 10.1016/j.bbadis.2014.10.006. Epub 2014 Oct 12. Review.

PMID:
25315300
7.

Neuroprotective effects of resveratrol in Alzheimer disease pathology.

Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR.

Front Aging Neurosci. 2014 Sep 11;6:218. doi: 10.3389/fnagi.2014.00218. eCollection 2014. Review.

8.

Adaptive and regulatory mechanisms in aged rats with postoperative cognitive dysfunction.

Bi Y, Liu S, Yu X, Wu M, Wang Y.

Neural Regen Res. 2014 Mar 1;9(5):534-9. doi: 10.4103/1673-5374.130084. Erratum in: Neural Regen Res. 2014;9(8):871. Wang, Mingshan [corrected to Wu, Mingshan].

9.

CaMKIV-dependent preservation of mTOR expression is required for autophagy during lipopolysaccharide-induced inflammation and acute kidney injury.

Zhang X, Howell GM, Guo L, Collage RD, Loughran PA, Zuckerbraun BS, Rosengart MR.

J Immunol. 2014 Sep 1;193(5):2405-15. doi: 10.4049/jimmunol.1302798. Epub 2014 Jul 28.

PMID:
25070845
10.

Resveratrol and Alzheimer's disease: message in a bottle on red wine and cognition.

Granzotto A, Zatta P.

Front Aging Neurosci. 2014 May 14;6:95. doi: 10.3389/fnagi.2014.00095. eCollection 2014. Review.

11.

AMPK at the nexus of energetics and aging.

Burkewitz K, Zhang Y, Mair WB.

Cell Metab. 2014 Jul 1;20(1):10-25. doi: 10.1016/j.cmet.2014.03.002. Epub 2014 Apr 10. Review.

PMID:
24726383
12.

CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Koppel J, Vingtdeux V, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P.

Mol Med. 2014 Mar 14;20:29-36. doi: 10.2119/molmed.2013.00140.revised.

13.

Autophagy Contributes to the Death/Survival Balance in Cancer PhotoDynamic Therapy.

Inguscio V, Panzarini E, Dini L.

Cells. 2012 Aug 3;1(3):464-91. doi: 10.3390/cells1030464.

14.

Involvement of 'stress-response' kinase pathways in Alzheimer's disease progression.

Mairet-Coello G, Polleux F.

Curr Opin Neurobiol. 2014 Aug;27:110-7. doi: 10.1016/j.conb.2014.03.011. Epub 2014 Apr 5. Review.

PMID:
24709372
15.

Signaling pathway cross talk in Alzheimer's disease.

Godoy JA, Rios JA, Zolezzi JM, Braidy N, Inestrosa NC.

Cell Commun Signal. 2014 Mar 28;12:23. doi: 10.1186/1478-811X-12-23. Review.

16.

Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications.

Wang J, Bi W, Cheng A, Freire D, Vempati P, Zhao W, Gong B, Janle EM, Chen TY, Ferruzzi MG, Schmeidler J, Ho L, Pasinetti GM.

Front Aging Neurosci. 2014 Mar 14;6:42. doi: 10.3389/fnagi.2014.00042. eCollection 2014.

17.

SIRT1 in neurodevelopment and brain senescence.

Herskovits AZ, Guarente L.

Neuron. 2014 Feb 5;81(3):471-83. doi: 10.1016/j.neuron.2014.01.028. Review.

18.

Optical and SPION-enhanced MR imaging shows that trans-stilbene inhibitors of NF-κB concomitantly lower Alzheimer's disease plaque formation and microglial activation in AβPP/PS-1 transgenic mouse brain.

Solberg NO, Chamberlin R, Vigil JR, Deck LM, Heidrich JE, Brown DC, Brady CI, Vander Jagt TA, Garwood M, Bisoffi M, Severns V, Vander Jagt DL, Sillerud LO.

J Alzheimers Dis. 2014;40(1):191-212. doi: 10.3233/JAD-131031.

19.

CB₂ receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease.

Koppel J, Vingtdeux V, Marambaud P, d'Abramo C, Jimenez H, Stauber M, Friedman R, Davies P.

Mol Med. 2013 Nov 8;19:357-64. doi: 10.2119/molmed.2013.00140. Erratum in: Mol Med. 2014;20():37. Corrected and republished in: Mol Med. 2014;20:29-36.

20.

AMPK activation--protean potential for boosting healthspan.

McCarty MF.

Age (Dordr). 2014 Apr;36(2):641-63. doi: 10.1007/s11357-013-9595-y. Epub 2013 Nov 19. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk